Global Metabolomics Biomarker Market 2025-2035

Description

List of Tables

Metabolomics Biomarker Market Size, Share & Trends Analysis Report By Application (Biomarker Discovery, Drug Discovery and Assessment, Toxicology Testing, Functional Genomics, Nutrigenomics, And Personalized Medicine.), By Technology (Chromatography, Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR) Spectroscopy, and Bioinformatics Tools & Services), By Organization Size (Large Enterprises and Small & Medium-Sized Enterprises (SMES)), and By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROS), and Diagnostic Laboratories), Forecast Period (2025-2035)

Metabolomics biomarker market was valued at $415.8 million in 2024 and is projected to reach $1,651.6 million by 2035, growing at a CAGR of 13.4% during the forecast period (2025-2035). The metabolomics market has grown rapidly as a result of metabolomics, which combines techniques to identify and analyze cellular metabolites using advanced analytical methods with statistical and multivariate methods for data extraction and interpretation. Significant investments have been made in the development of analytical methods for different cellular products, such as gene expression (transcripts), proteins, and metabolites. This method has been applied to many different biological systems using GC-MS, including plants, microbial, urine, and plasma. Metabolomics uses additional studies such as LC-MS/MS, GC-MS, and/or NMR to identify and characterize as many metabolites as possible. It can additionally be used for metabolic fingerprints (or footprints of exogenous and/or secreted metabolites).

Personalized medicine is increasingly driven by the need for tailored treatments based on individual metabolic profiles, particularly in oncology. The rising prevalence of chronic diseases such as cancer and neurological disorders boosts the demand for improved diagnostic and prognostic biomarkers. Additionally, heightened investment in metabolomics research and advancements in technology enhance market opportunities. Metabolomics also offers valuable insights into cellular processes and disease mechanisms, potentially improving the efficiency and success of drug discovery and development.

Market Dynamics

Advancements in Genomic Technologies

The development of next-generation sequencing (NGS) platforms and polymerase chain reaction (PCR) technologies has significantly enhanced the ability to detect and analyze genomic biomarkers. These advancements facilitate early disease detection, personalized treatment plans, and the development of targeted therapies, thereby driving market growth

Increasing Demand for Personalized Medicine

There is a growing emphasis on personalized medicine, where treatments and healthcare strategies are tailored to individual genetic profiles. Genomic biomarkers play a crucial role in identifying patients who are most likely to benefit from specific therapies, leading to more effective and efficient healthcare outcomes

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases, such as cancer and neurological disorders, has heightened the need for effective diagnostic tools and personalized treatment options. Genomic biomarkers aid in the early detection and monitoring of these conditions, contributing to improved patient management and outcomes.

Market Segmentation

Based on the application, the market is segmented into biomarker discovery, drug discovery and assessment, toxicology testing, functional genomics, nutrigenomics, and personalized medicine.
Based on the technology, the market is segmented into chromatography, mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and bioinformatics tools & services.
Based on the organization size, the market is segmented into large enterprises and small & medium-sized enterprises (SMEs).
Based on the end-user industry, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROS), and diagnostic laboratories.

Biomarker Discovery is the Largest Segment in the Global Metabolomics Biomarker Market

The biomarker discovery application segment holds the largest share. This dominance is attributed to the increasing utilization of metabolic biomarkers to assess patients' pathophysiological health conditions. The integration of advanced technologies in developing metabolomic biomarkers further contributes to the growth of this segment.

Spherical Insights

Among the various segments in the global genomic biomarker market, oncology stands out as the largest and fastest-growing segment. The increasing use of genomic biomarkers in cancer diagnosis and treatment is driving this growth. The rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments are key factors contributing to the expansion of this segment.

Pharmaceutical and Biotechnology Companies: A Key Segment in Market Growth

The pharmaceutical and biotechnology companies segment is experiencing significant growth within both the metabolomics and genomic biomarker markets. In the metabolomics sector, these companies are increasingly integrating metabolomic analyses into drug discovery and development processes to identify potential therapeutic targets and biomarkers for disease. Similarly, in the genomic biomarker market, pharmaceutical and biotechnology firms are leveraging genomic insights to develop personalized therapies and companion diagnostics, enhancing the efficacy of treatments. The collaboration between these companies and research institutions is accelerating the translation of biomarker discoveries into clinical applications, thereby driving the expansion of both markets.

Regional Outlook

The global metabolomics biomarker industry is distributed by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Global Metabolomics Biomarker Market and Deployment in Asia-Pacific

The Asia-Pacific (APAC) metabolomics biomarker market is witnessing rapid growth due to the region's accelerated digital transformation, cloud adoption, and increasing cyber threats targeting enterprises. Governments and private organizations are increasingly investing in cybersecurity initiatives to protect sensitive data across sectors such as BFSI, IT & telecom, manufacturing, and e-commerce. The region is also seeing rising awareness of compliance requirements, such as data localization laws, which mandate independent security validation and testing.

Cloud-based Metabolomics Biomarker in APAC is gaining significant traction as organizations move away from legacy on-premises systems to scalable, flexible cloud environments. Cloud PTaaS offerings allow continuous vulnerability assessment, integration with CI/CD pipelines, and automation of testing workflows, making it a preferred choice for enterprises seeking cost-effective and efficient solutions. On-premises deployment, while still relevant for high-security environments, is gradually seeing slower adoption in comparison to cloud-based models.

North America Maintains Strong Market Position

North America holds a significant share of the global metabolomics Biomarker market. The US stands as the dominant force in the global metabolomics biomarker market, a position bolstered by its robust healthcare infrastructure, substantial investments in research and development, and a favorable regulatory environment. This leadership is further reinforced by the presence of major academic and research institutions, alongside pharmaceutical and biotechnology companies, which collectively propel market growth in this region. Additionally, in 2024, North America commanded the largest share of the metabolomics market, accounting for approximately 40% of the global market. This dominance is attributed to the US' extensive network of over 6,600 biotech companies, which are committed to innovation aimed at addressing complex medical problems. Additionally, the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, has intensified the demand for advanced diagnostic tools and personalized treatment approaches, further driving the growth of the metabolomics market.

Moreover, the integration of artificial intelligence (AI) into metabolomics research has significantly enhanced data analysis capabilities, enabling more efficient identification of disease-specific biomarkers and prediction of drug responses. AI-powered algorithms facilitate rapid data processing and interpretation, thereby accelerating the pace of research and development in metabolomics.

Market Players Outlook

The major companies operating in the global metabolomics biomarker market include Agilent Technologies, Bio-Rad Laboratories, Bruker Corp., Danaher Corp., Thermo Fisher Scientific, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In September 2025, Biognosys expanded its contract research organization services to include quantitative biocrates metabolomics and lipidomics for multiomics drug discovery and clinical research. The services will be offered in Europe and the US from Biognosys' Boston laboratory. The expansion complements Biognosys' mass spectrometry-based proteomics services and strengthens its global multiomics service portfolio.
In February 2025, Metabolon launched an integrated bioinformatics platform that includes multiomics predictive modeling, latent factor analysis, and multiomics pathway analysis using public tools like Reactome. This functionality allows users to upload and integrate diverse omics data, evaluate model performance, identify latent factors, and map metabolites to other omics entities using Reactome's comprehensive reference of biological pathways.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global metabolomics biomarker market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023965

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Metabolomics Biomarker Market Sales Analysis - Application | Technology | End-User ($ Million)
Metabolomics Biomarker Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Metabolomics Biomarker Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Metabolomics Biomarker Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Metabolomics Biomarker Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Metabolomics Biomarker Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Metabolomics Biomarker Market Revenue and Share by Manufacturers
Metabolomics Biomarker Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Agilent Technologies
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bio-Rad Laboratories
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Bruker Corp.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Danaher Corp.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Thermo Fisher Scientific
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Metabolomics Biomarker Market Sales Analysis By Application ($ Million)

5.1. Biomarker Discovery
5.2. Drug Discovery and Assessment
5.3. Toxicology Technology
5.4. Functional Genomics
5.5. Nutrigenomics
5.6. Personalized Medicine

6. Global Metabolomics Biomarker Market Sales Analysis By Technology ($ Million)

6.1. Chromatography
6.2. Mass Spectrometry (MS)
6.3. Nuclear Magnetic Resonance (NMR) Spectroscopy
6.4. Bioinformatics Tools & Services

7. Global Metabolomics Biomarker Market Sales Analysis By End-User ($ Million)

7.1. Pharmaceutical and Biotechnology Companies
7.2. Academic and Research Institutes
7.3. Contract Research Organizations (CROs)
7.4. Diagnostic Laboratories

8. Regional Analysis

8.1. North American Metabolomics Biomarker Market Sales Analysis - Application | Technology | End-User ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Metabolomics Biomarker Market Sales Analysis - Application | Technology | End-User ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Metabolomics Biomarker Market Sales Analysis - Application | Technology | End-User ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Metabolomics Biomarker Market Sales Analysis - Application | Technology | End-User ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa